Latest Market Research Updates: March 2017

Friday, 31 March 2017

Global Viral Infections Market Will Reach At $117.6 billion in 2021

Latest industry research report on: Global Viral Infections Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Viruses are infectious particles comprising a nucleic acid core – consisting of either DNA or RNA – and a protein coat known as a capsid. Infections attributable to viral pathogens are transmitted, directly or indirectly, from one person to another or from animal to human. Viruses replicate by exploiting the resources of their host cells, usually to the detriment of the host. As viral pathogens are exceptionally diverse, the morbidity associated with viral infections varies significantly depending on the virus in question. This report covers all viral infections, although particular focus is given to four key indications within this disease cluster: Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) and influenza. The global viral infections market was valued at $74.0 billion in 2014, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 6.8%, reaching $117.6 billion in 2021. Key drivers of this growth will be the expanding treatment population and uptake of recently approved highly priced antiviral agents, as well as promising late-stage candidates that are expected to be priced highly.

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/716911

Scope

The viral infections market is large and growing rapidly

How do epidemiology trends differ among the key indications?
What therapeutic options exist for preventing and treating viral infections?
Which products and companies dominate the market?

The pipeline is innovative and diverse

What is the proportion of early- to late-stage pipeline products?
Which molecular targets are most prominent within the pipeline?
How do the key indications differ in terms of molecule type?

Considerable market growth is anticipated throughout 2021

Which products will contribute to this growth most significantly?
Will the current market leaders retain their dominance over the forecast period?

Deal values for licensing and co-development deals range considerably

How many strategic consolidations have been completed in the past decade?
Which types of assets attract the largest deal values?

Reasons to buy

This report will allow you to -

Examine the current clinical and commercial landscape by considering disease pathogenesis, treatment options and key marketed products.
Appreciate how the four key indications - HIV, HCV, HBV and influenza - differ in terms of epidemiology, symptoms and co-morbidities and complications.
Identify trends and developments, in terms of molecule type and molecular target, within the overall viral infections pipeline, as well as for each of the four key indications.
Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
Recognize how the evolving treatment landscape will drive market growth to 2021 and understand the contributions that different products, molecular targets and companies will make to this growth.
Understand how strategic consolidations have shaped the current pipeline and marketed product landscapes.

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Global Non-Hematological Cancers Market Expected To Grow At $141 billion in 2021

Latest industry research report on: Global Non-Hematological Cancers Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of global cancer prevalence. The key cancer indications of this report, namely breast, colorectal, lung and prostate cancer, constitute approximately 51% of global cancer prevalence.

The risk of cancer increases greatly in patients over the age of 65. As populations are projected to increase, with aging and increasing incidence of obesity, the prevalence of cancer as a genetic disease is only anticipated to increase, thereby acting as a driver for revenue growth. Typically, chemotherapy has curative or palliative uses depending on whether the patient’s tumors are resectable or unresectable, respectively; however, use of chemotherapies is often reliant on performance status, which is lacking in many cancer patients.

There has been a shift towards developing targeted therapies, which by their nature have less toxicity associated with their use and as a result can be administered to greater numbers of cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/716914

Scope

Global revenues for the non-hematological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.86%, from $73 billion in 2014 to $141 billion in 2021

What is the generic penetration?
Which drugs will achieve blockbuster status?

Overall, there are 6,484 oncology products in the pipeline, which make it the largest therapy area pipeline

How does the composition of the pipeline compare with that of the existing market?
What mechanisms of action are most common for pipeline drugs?

18 of the top 20 pharmaceutical companies will market non-hematological cancer drugs in the forecast period

How is their revenue share of the non-hematological cancer market set to change?
What CAGR will these companies register in the forecast period?

Reasons to buy

This report will allow you to -

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis
Visualize the composition of the non-hematological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
Analyze the non-hematological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
Understand the growth in patient epidemiology and market revenues for the non-hematological cancer market globally and across the key players and product types
Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various non-hematological cancers
Identify commercial opportunities in the non-hematological cancer deals landscape by analyzing trends in licensing and co-development deals

About us

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Global Schizophrenia and Associated Indications Market Size, Industry Analysis, Innovation, Overview, Growth Rate, Share and Forecasts

Latest industry research report on: Global Schizophrenia and Associated Indications Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Schizophrenia is a severe mental disorder that is characterized by abnormal social behavior and failure to recognize what is real; its symptoms are broadly divided into positive, negative and cognitive. The treatment of schizophrenia is multi-factorial and includes medical, psychological and psychosocial inputs. Antipsychotic medication is the main pharmacological agent used, along with counselling, job training, and social rehabilitation. Both typical and atypical antipsychotics are used, and the choice of medication is usually left to the discretion of the treating physician. Clozapine, which is an atypical antipsychotic that binds to serotonin and dopamine receptors, is often given to patients who do not improve with other antipsychotics.

Current treatments, although effective for positive symptoms, have not proven as effective for negative symptoms and cognitive dysfunction, nor are there are any disease-modifying drugs currently available. The pipeline for schizophrenia is small, particularly given the large patient population, it also has low levels of innovation in comparison to other psychiatric indications in the pharmaceutical industry. However, the overall level of innovation in the pipeline for schizophrenia-related indications (which includes depression, panic disorders, obsessive compulsive disorder, post-traumatic stress disorder and cognitive deficit) is far higher, with these related products having the potential to provide some benefit to patients with schizophrenia.

Download Sample copy of this Report at :

http://www.marketresearchreports.biz/sample/sample/716912

Scope

The current clinical landscape of schizophrenia

What is the pathophysiology of schizophrenia?
How is schizophrenia diagnosed?
What are the current treatment options?

The schizophrenia pipeline is small, although there is a much larger pipeline for its related indications.

What are the common targets and mechanisms of action of pipeline therapies?
Will the pipeline address unmet needs such as a lack of diverse treatment options for schizophrenia patients, particularly those with negative or cognitive symptoms?
What is the composition of the pipeline for schizophrenia-related indications, and will they be of benefit to schizophrenia patients?

First-in-class products and targets currently within the schizophrenia pipeline

What are the most promising first-in-class targets for schizophrenia?

Detailed outlook on first-in-class targets and whether they have other therapeutic potential across the industry

Licensing deals are the most common form of strategic alliance in schizophrenia

How do deal frequency and value compare between target families and molecule types?
How do licensing and co-development deals compare between first-in-class and non-first-in-class profiles?

Reasons to buy

This report will allow you to -

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies
Visualize the composition of the schizophrenia market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
Analyze the schizophrenia pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating schizophrenia.
Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
Identify commercial opportunities in the schizophrenia deals landscape by analyzing trends in licensing and co-development deals and producing a list of schizophrenia therapies that are not yet involved in deals, and may be potential investment opportunities.

About us

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Global Gastric Cancer Market Size, Industry Analysis, Emerging Evolution, Overview, Growth Rate, Share and Forecasts

Latest industry research report on: Global Gastric Cancer Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The gastric cancer market is undergoing a gradual change, from a focus on generic chemotherapy regimens to complex treatment landscape based on targeted therapies. Recently the market has witnessed the approval of efficacious therapies such as Cyramza, but this only benefits a small subset of patients. As the understanding of disease pathophysiology increases, new targets need to be identified and converted into improved therapeutic options. The current pipeline shows strong promise, as it shows a gradual shift from generic cytotoxic therapies to more diverse targeted therapies.

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/713902

Scope

What is the pathophysiology of gastric cancer?
How is gastric cancer diagnosed?
What are the current treatment options?
What are the common targets and mechanisms of action of pipeline therapies?
Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer patients?
What implications will the increased focus on targeted therapies have on the future of gastric cancer treatment?
What are the most promising first-in-class targets for gastric cancer?
Will the current first-in-class targets have a broader therapeutic potential across the industry?
How do deal frequency and value compare between target families and molecule types?
How do licensing and co-development deals compare between first-in-class and non-first-in-class profiles?

Reasons to buy

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies
Visualize the composition of the gastric cancer market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
Analyze the gastric cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating gastric cancer.
Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
Identify commercial opportunities in the gastric cancer deals landscape by analyzing trends in licensing and co-development deals and producing a list of gastric cancer therapies that are not yet involved in deals, and may be potential investment opportunities.

About us

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Thursday, 30 March 2017

Global Generic Drugs Market Size, Industry Analysis, Technology advancement, Overview, Growth Rate, Share and Forecasts

Latest industry research report on: Global Generic Drugs Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

GBI Research’s latest report “The Future of Generic Drugs and Strategies for Commercial Success” discusses trends in the global generic drugs market, and the evolving business strategies being adopted and leveraged by generic drug companies around the world. GBI Research conducted an extensive and targeted industry survey of experts from top global generic drug companies, to gather opinions on the trends and future commercial prospects of the generic drugs market. The findings from the survey and results from extensive data analysis and secondary research efforts have been triangulated with GBI’s own analytical views to provide an objective assessment that is comprehensive in outlook.

The generic drugs market has seen rapid expansion for more than 30 years, and consistently achieves higher annual growth rates than the overall pharmaceutical market. The increase in generic drug activity can be primarily attributed to the promise of significant revenues from blockbuster drugs nearing patent expiry. In the US – the largest generic drugs market by revenue – the number of generic drug approvals hit a record high in 2015, due to a new program that aimed to speed up approvals. There has also recently been a surge in the number of industry-transforming mergers and acquisitions, with companies looking to consolidate their position in this highly lucrative market.

Sample copy of this Report @http://www.marketresearchreports.biz/sample/sample/848086

The results of GBI’s latest industry survey provide insightful analyses from different expert panels, including R&D and commercial, and highlight trends observed in key geographical markets. The survey examined key commercial issues and recent developments in the generic drugs market, such as the reasons behind the surge in mergers and acquisitions, and the likely effects on market dynamics. It covered important factors currently driving or restraining the market, prospects for key therapy areas expected to exhibit significant levels of genericization in the coming years, and the most promising emerging markets for generic companies in terms of revenue potential. Additionally, the survey examined common business strategies and regulations being leveraged by global generic drug companies for market expansion.

The report covers key small molecule drugs whose patents will expire in the coming years, providing an in-depth assessment of potential generic competition, expected launch dates and the overall impact on global branded revenues to 2021. The top global generic drug companies by revenue are also examined, including financial performance and recent activity within the market.

This new report adds to our unique portfolio of trusted industry analyses, which enable our clients to assess the most promising commercial areas in the market and identify key business opportunities.

Scope

What is the current value of the generic drugs market, and how will market dynamics change in the coming years?
Will the US continue to dominate the market?
Which therapy areas will witness the highest level of genericization in the next five years?

Drivers and restraints in the generics industry:

What are the most important factors promoting generic drug usage at a global level?
What are the most important factors hindering or delaying generic drug approvals?
Will governments worldwide continue their efforts to promote generic drug usage?
How will global demographic trends impact demand for generic drugs?
Which emerging economies are the most promising for generic drugs companies?
Are generic drugs still negatively perceived?
How are pricing pressures and rising costs affecting generic drug manufacturers?
Generic drugs pipeline for top small molecule drugs in the market:
What will be the revenue impact for key small molecule drugs whose patents expire in the near future?
What are the key patent expiry dates for these small molecules and what level of generic competition should they expect?
Strategies for commercial success:
What are the most popular strategies or regulations being adopted and leveraged by generic drug manufacturers?
What governmental policies are significantly influencing generic drug usage?
What will be the impact of compulsory licenses in emerging markets?
Mergers and acquisitions in the global generic drugs market:
What are the most important factors contributing to the surge in M&A activity in the generic drugs market?
How will market dynamics be affected by continued consolidation in the generic drugs market?
What have been the most important transactions in the generic drugs industry in recent years?
Top global generic drugs companies:
How have top generic drugs companies performed in recent years?
What are the prospects for top generic drugs companies?

Reasons to buy

This report will allow you to

Gain insightful analyses and understanding of market dynamics: This report comprehensively describes and assesses the most important factors driving and restraining the generic drugs market. It assesses pertinent commercial and regulatory aspects of the industry by combining survey results with proprietary in-house expertise and extensive secondary research efforts.
Assess the generic drugs pipeline for top small molecule drugs in the market: Our study provides prospects for these drugs beyond their patent expiries, including potential generic competition, expected launch dates and revenue forecasts to 2021.
Evaluate the strategies used by companies to promote generic drug usage: This report provides insights regarding the various commercial strategies being adopted and leveraged by generic drug companies to promote their therapies.
Understand government policies and strategies to promote generic drug usage: This report assesses current strategies and regulations implemented by governments in key geographic markets to promote generic drug usage.
Gain insight on mergers and acquisitions in the global generic drugs market: This report describes industry-transforming mergers and acquisitions that have occurred in recent years, the reasons behind the recent surge in these types of transactions, and their likely impact on market dynamics.

About us

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Global Prostate Cancer Market Size, Industry Analysis, Technology advancement, Overview, Growth Rate, Share and Forecasts

Latest industry research report on: Global Prostate Cancer Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Prostate cancer (PC) is a type of cancer that affects the prostate gland of the male reproductive system, and is the most common non-cutaneous malignant cancer in men. Internationally, it is the sixth-largest cancer-related cause of death in men. Those aged over 50 are at the greatest risk of developing PC, with advanced age being the primary risk factor for the disease.

Most cases of PC (95%) are classed as adenocarcinomas, a type of cancer that arises in the cells of glands. Around 4% of cases display transitional cell morphology, and originate from the urothelial lining of the prostatic urethra. In rare cases prostate cancer may present with neuroendocrine morphology, and can arise from neuroendocrine stem cells present in the prostate. PC begins with the conversion of normal semen-secreting prostate gland cells into cancerous cells. In 75% of cases these start developing in the peripheral zone of the prostate – the site closest to the rectum.

PC is often asymptomatic, which can lead to a lack of diagnosis in the early stages of the disease, rendering treatment less effective once a diagnosis is made. If symptoms are present or if a diagnosis has been made during a physician's examination, depending on the stage of the disease, the cancer may be treated through surgical removal of cancerous cells, radiation therapy, or a combination of both.

Sample copy of this Report @http://www.marketresearchreports.biz/sample/sample/915800

The PC market consists of therapies for both hormone-sensitive and castration-resistant forms of the disease. The options available for the two forms are notably different, with hormonal therapies used in the hormone-sensitive stage, and chemotherapy or targeted therapies used in the castration-resistant stage. Castration-resistant PC relates to both symptomatic and asymptomatic forms of the disease that no longer respond to hormonal therapy.

Hormonal therapies are widely used across multiple stages of hormone-sensitive disease, and the goal is to halt PC growth stimulated by testosterone. There are two methods used to treat PC through targeting hormones. The first is androgen deprivation therapy (ADT) using gonadotropin releasing hormone (GnRH) agonists and antagonists, and the second is androgen receptor (AR) blockage, using compounds termed anti-androgens.

The differences between many of these products are relatively nuanced, and must be understood fully by companies seeking to position a novel drug in this market. This tabular heatmap framework, designed to provide an easily digestible Summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the PC market and late-stage pipeline. These are split along lines of therapy, and are therefore reflective of the treatment algorithm.

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and comparison groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Scope

What are the clinical characteristics of currently approved therapies for PC, in terms of specific safety and efficacy parameters?
What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are most closely linked to them?
Which novel classes of therapy are expected to emerge in the treatment of PC?
Which targets do these therapies act upon?
Which sub-types of patients could potentially benefit from these new products?

Reasons to buy

Understand the current clinical landscape by considering the treatment options available for each patient segment.
Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
Understand the relative strengths and weaknesses of the studies used to gather these data.
Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.

About us

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Global Respiratory disorders market Expected To Grow At $46.6 billion till year 2022.

Latest industry research report on: Global Respiratory disorders Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

The respiratory therapy area consists of indications that affect the respiratory system in different ways, such as the scarring of lung tissue, and excessive production of mucus in the airways, thereby decreasing lung function. Some of the key indications in this therapy area include asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.

Visit Complete Report @ http://www.marketresearchreports.biz/analysis/811827

The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms, rather than the cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. This is most notable in CF, where patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The COPD and asthma treatment landscapes employ similar symptomatic treatments, including bronchodilators and inhaled corticosteroids.

However, over the past decade the treatment of respiratory disorders has developed significantly, as has the importance for novel therapies and targeted therapies. The approval of the products Orkambi and Kalydeco, in 2014 and 2012 respectively, gave patients disease-modifying treatment options for CF. Another important entry was the first biologic drug - omalizumab - approved in 2014 for the treatment of severe asthma. The trend of developing targeted therapies continued with the approval of the maintenance treatment Nucala (mepolizumab) in November 2015.

Sample copy of this Report @http://www.marketresearchreports.biz/sample/sample/811827

Although the more traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder pipeline, the pipeline also contains promising targeted biologic therapies, which reflects their growing prominence in this therapy area. Overall, 908 products are currently in active in development for respiratory disorders.

Scope

The respiratory disorders market is characterized by entrenched, commercially successful therapies.

Which classes of drug dominate the market?
What additional benefits have newly approved therapies brought to the market?
What are the future prospects for the leading brands?

The pipeline contains a range of molecule types and molecular targets, with a growing presence of targeted therapies.

Which molecular targets appear most frequently in the pipeline?
What are the commercial prospects for the most promising late-stage pipeline products?

Respiratory disorders clinical trials have an overall attrition rate of 89.1%.

What are the failure rates at individual phases of clinical development?
How do the key respiratory disorders compare in terms of clinical trial failure rate?

The respiratory disorders market is forecast to rise from a value of $28.1 billion in 2015 to $46.6 billion in 2022, at a CAGR of 7.5%.

How much of a role will pipeline product approvals play in market growth?
Are the large number of recently approved products expected to drive market growth?
Will generic competition have a significant impact on the market over the forecast period?
Which products face generic competition?

Big pharma holds a notable presence in the market.

What are the leading companies in terms of market share?
Which companies are forecast to experience the greatest growth in market share?
Which company will hold the largest market share in 2022?
How dependent are the key companies on this disease cluster for revenue?
Which companies rely heavily on this disease cluster for revenue?

Reasons to buy

This report will allow you to -

Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment landscape in respiratory disorders.
Assess the current treatment landscape, with product profiles on prominent marketed therapies, including revenue forecasts.
Analyze the respiratory disorders pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from respiratory disorder products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
Identify commercial opportunities in the respiratory disorder deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

About us

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz